CNS & Neurological Disorders - Drug Targets
Title:Conclusive Article: Sorting the Good from the Bad: The Different Approaches to Predict Cognitive Properties of New Symptomatic Drug Candidates for Neurodegenerative Diseases in Early Development
Volume: 15 Issue: 7
Author(s): Julie Deguil, Alexandra Auffret, Esther Schenker, Fabienne Aujard, Yves Lamberty, David Bartrès-Faz, María T. Herrero, Olivier Blin, Joëlle Micallef, Jill C. Richardson and Régis Bordet
Affiliation:
Export Options
About this article
Cite this article as:
Deguil Julie, Auffret Alexandra, Schenker Esther, Aujard Fabienne, Lamberty Yves, Bartrès-Faz David, Herrero T. María, Blin Olivier, Micallef Joëlle, Richardson C. Jill and Bordet Régis, Conclusive Article: Sorting the Good from the Bad: The Different Approaches to Predict Cognitive Properties of New Symptomatic Drug Candidates for Neurodegenerative Diseases in Early Development, CNS & Neurological Disorders - Drug Targets 2016; 15 (7) . https://dx.doi.org/10.2174/187152731507160808203445
DOI https://dx.doi.org/10.2174/187152731507160808203445 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Effects of the KIBRA Single Nucleotide Polymorphism on Synaptic Plasticity and Memory: A Review of the Literature
Current Neuropharmacology Electrodeposition of Cu-Ni Coatings for Marine Protection of Mild Steel
Innovations in Corrosion and Materials Science (Discontinued) Are Carbonic Anhydrase Inhibitors Suitable for Obtaining Antiobesity Drugs ?
Current Pharmaceutical Design Structure and Mechanism of Action of Tau Aggregation Inhibitors
Current Alzheimer Research Arachidonate Cascade in the Intensive Insulin Therapy for Critically Ill Patients with Sepsis: Roles of Prostaglandins on Hyperglycemia-Impaired Immunity
Letters in Drug Design & Discovery Identification of Crucial Genes and Diagnostic Value Analysis in Major Depressive Disorder Using Bioinformatics Analysis
Combinatorial Chemistry & High Throughput Screening Early Diagnosis of Alzheimers Disease: Is MCI Too Late?
Current Alzheimer Research Upregulation of DLX2 Confers a Poor Prognosis in Glioblastoma Patients by Inducing a Proliferative Phenotype
Current Molecular Medicine Dangerous Liaisons: Tau Interaction with Muscarinic Receptors
Current Alzheimer Research 3D-QSAR Analysis on Pyrrolopyridine Analogs as Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MK-2) Inhibitors
Letters in Drug Design & Discovery Acknowledgements to Reviewers
Current Alzheimer Research In vitro Study of Furazano[3,4-b]quinoxaline 1-Oxides as Potential ΝΟ Releasing Agents
Letters in Drug Design & Discovery The Diagnostic Value of CSF Amyloid-β<sub>43</sub> in Differentiation of Dementia Syndromes
Current Alzheimer Research Functional, Global and Cognitive Decline Correlates to Accumulation of Alzheimers Pathology in MCI and AD
Current Alzheimer Research Development of BACE1 Inhibitors for Alzheimers Disease
Current Medicinal Chemistry Developmental Immunotoxicity (DIT) in Drug Safety Testing: Matching DIT Testing to Adverse Outcomes and Childhood Disease Risk
Current Drug Safety Intramuscular Route of Administration Increases Potency in Eliciting Cocaine-Induced Behavioral Sensitization
Current Psychopharmacology Antioxidant Activity of Resveratrol Analogs
Letters in Drug Design & Discovery Inhibition of Glycolysis and Glutaminolysis: An Emerging Drug Discovery Approach to Combat Cancer
Current Topics in Medicinal Chemistry Recognition of Nucleic Acids by Toll-Like Receptors and Development of Immunomodulatory Drugs
Current Medicinal Chemistry